SILEO® is the first-and-only Health
Canada-approved product for the alleviation of acute anxiety and
fear associated with noise in dogs
TORONTO, Oct. 29,
2024 /CNW/ - Grey Wolf Animal Health Corp. (TSXV:
WOLF) ("Grey Wolf" or the "Company"), a Canadian diversified animal
health company, today announced the Canadian commercial launch of
SILEO® (dexmedetomidine hydrochloride oromucosal gel) to veterinary
clinics throughout Canada. SILEO builds on Grey Wolf's
portfolio dedicated to behaviour and anxiety health in companion
animals. Dogs that experience fear and anxiety in response to
loud noise such as fireworks now have a new treatment option.
SILEO is available from veterinarians by prescription and can be
administered at home by pet owners to help calm dogs without
sedation.
"We are excited to launch SILEO in Canada, a solution for alleviating acute
anxiety and fear associated with noise in dogs. We know that
noise-related events can be stressful for both pets and pet owners.
SILEO works by calming without sedating so pets can continue to
interact with their owners," said Dr. Ian
Sandler, Chief Veterinary Medical Officer and Founder of
Grey Wolf. "This prescription medication is another way Grey Wolf
is supporting veterinarians, pets and pet owners in Canada."
About SILEO
SILEO is an oromucosal gel formulation of dexmedetomidine, a
potent and selective alpha-2 adrenoceptor agonist designed to block
noradrenaline release thereby reducing the physiological and
behavioural manifestations of fear and anxiety. SILEO is
administered oromucosally between the dog's cheek and gums, which
limits the amount of dexmedetomidine available in the body and
provides a calming effect without sedating.
For more information about SILEO, please visit
www.products.greywolfah.com/sileo.
IMPORTANT SAFETY INFORMATION
Do not use SILEO in dogs with severe cardiovascular disease,
respiratory, liver or kidney diseases, or in conditions of shock,
severe debilitation or stress due to extreme heat, cold or fatigue.
Do not use SILEO in dogs with known cases of hypersensitivity to
dexmedetomidine or any of the excipients. Do not use in dogs
obviously sedated from previous dosing. SILEO should not be
administered in the presence of pre-existing hypotension, hypoxia
or bradycardia. SILEO has not been evaluated in dogs younger than
six weeks of age or in dogs with dental or gingival disease that
could have an effect on the absorption of SILEO. SILEO has not been
evaluated for use in breeding, pregnant or lactating dogs. For full
Prescribing Information, go to
www.products.greywolfah.com/sileo.
SILEO® is a registered trademark of Orion Pharma
Animal Health. It is manufactured by Orion Corporation ("Orion")
and distributed by Grey Wolf under an exclusive agreement with
Orion Corporation.
About Orion Corporation
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being for over a hundred years. Orion develops,
manufactures and markets human and veterinary pharmaceuticals and
active pharmaceutical ingredients. Orion's net sales in 2023
amounted to EUR 1,190 million and the
company had about 3,600 employees at the end of the year. Orion's A
and B shares are listed on Nasdaq Helsinki.
About Grey Wolf Animal Health Corp.
Grey Wolf Animal Health Corp., headquartered in Toronto, Canada, is a diversified animal
health company founded by a veterinarian to bring to market a
broad portfolio of products that meets the unmet needs of
veterinarians, clinics and pets. The Company's strategy is to
in-license, acquire or develop innovative prescription and
non-prescription products for commercialization in the veterinarian
channel in Canada. For additional
information, please visit: www.greywolfah.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this news release.
Forward Looking Statements
This news release includes certain statements that may be
deemed "forward-looking statements." All statements in this new
release, other than statements of historical facts, that address
events or developments that the Company expects to occur, are
forward-looking statements. This information includes statements
concerning SILEO and its ability to alleviate acute anxiety and
fear associated with noise in dogs. Forward-looking statements
are statements that are not historical facts and are generally, but
not always, identified by the words "expects," "plans,"
"anticipates," "believes," "intends," "estimates," "projects,"
"potential," and similar expressions, or that events or conditions
"will," "would," "may," "could," or "should" occur.
Forward-looking statements are based on the beliefs, estimates and
opinions of the Company's management on the date the statements are
made. Except as required by applicable securities laws, the Company
undertakes no obligation to update these forward-looking statements
in the event that management's beliefs, estimates or opinions, or
other factors, should change
SOURCE Grey Wolf Animal Health Corp.